Phase I/II study of pre-operative intensity-modulated radiation therapy (IMRT) and docetaxel for high-risk prostate cancer: a platform for radiosensitizer development

Mark Garzotto, MD, Arthur Hung, MD, Tomasz Beer, MD, Paige E. Farris, MSW
Portland VA Medical Center and Division of Urology, Division of Urology and the Oregon Cancer Institute, Oregon Health & Science University, Portland, Ore.

Abstract

Background: Treatment results from both adjuvant and salvage radiation trials show that local recurrence after prostatectomy for high-risk cancer is common. Pre-operative chemoradiation has the potential to reduce local recurrences and improve survival, but has not been studied in prostate cancer. The establishment of a pre-prostatectomy model that includes radiation would facilitate and promote the discovery of novel radiosensitizers.

Methods: The primary objectives of this trial are to define the maximal tolerated dose (MTD) of the combination of IMRT and docetaxel and to determine the pathologic response rate at the Phase II dose. Secondary objectives include PSA responses, relapse-free survival, surgical margin status, HRQOL and tissue and serum biomarker effects. Eligible patients have: 1) C72b or resectable C73a tumors, 2) a serum PSA ≥ 15 mg/ml, or 3) a primary Gleason grade ≥ 4. All patients undergo pre-treatment placement of prostatic fiducial seed markers along with cryopreservation of study-designated tumor tissue. Patients receive 45 Gy IMRT over 25 fractions to the prostate and seminal vesicles. Prostatectomy is performed within 4 to 6 weeks after completion of chemoradiation during which time additional tumor tissues are cryopreserved for biomarker analyses. Escalating doses of weekly docetaxel are given for 5 consecutive weeks during IMRT. A minimum of 3 patients are accrued at each dose levels of 0 mg/m², 10 mg/m², 20 mg/m² and 30 mg/m². The dose escalation continues to a planned dose of 30 mg/m² or until one or more patients per cohort experienced a dose-limiting toxicity (DLT), defined as greater than grade 3 non-hematological (excluding hyperglycemia) or grade 4 hematological toxicity. After definition of the MTD, a minimum of 15 additional patients are accrued at the Phase II dose. Minimum accrual target is 27 patients assuming no DLTs.

Primary Study Objectives

1. To define the maximal tolerated dose (MTD) of the combination radiation (45 Gy) and docetaxel (with a pre-planned ceiling of doctaxel 30 mg/m²).
2. To determine the pathologic response rate (complete response defined as absence of detectable cancer in prostatectomy specimen) at the Phase II dose.

Secondary Study Objectives

PSA response, relapse-free survival, surgical margin status, HRQOL and biomarker changes.

Background:

1. PSA failure rates exceed 50% at 5 years after radiation or surgery.1
2. 15 yr-PCSM is 34% with surgery alone for high-risk disease.2
3. Data from adjuvant therapy trials now show that local disease is a major source of cancer recurrence after surgery.3,4


Unmet Needs:

1. Strategies to improve local control after surgery
2. Lack of a platform to test novel radiosensitizers

Materials and Methods

Inclusion Criteria

1. Histologically confirmed adenocarcinoma of the prostate
2. Prostatectomy planned as primary therapy
3. 10 year or longer life expectancy
4. ECOG Performance status < 2
5. Any of the following high risk features:
   - Clinical stage T2b (palpable bilateral involvement) or T3 OR
   - PSA > 15 mg/ml OR
   - Gleason grade > 4+3 (4+3, 4+4)
6. No evidence of bone metastases on bone scan
7. No evidence of lymph nodes > 2 cm in diameter on pelvic CT scan
8. PSA > 40 ng/ml

Secondary Study Objectives

PSA response, relapse-free survival, surgical margin status, HRQOL and biomarker changes.

Background:

1. PSA failure rates exceed 50% at 5 years after radiation or surgery.1
2. 15 yr-PCSM is 34% with surgery alone for high-risk disease.2
3. Data from adjuvant therapy trials now show that local disease is a major source of cancer recurrence after surgery.3,4


Unmet Needs:

1. Strategies to improve local control after surgery
2. Lack of a platform to test novel radiosensitizers

Schedule of Events

<table>
<thead>
<tr>
<th>Pre-Treatment</th>
<th>Weekly</th>
<th>Pre-Op</th>
<th>Post-Op</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening and informed consent</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Exam</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone Scan</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pelvis CT scan (if PSA ≥ 40 ng/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate biopsy specimens (10)</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>PSA</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>CBC/differential</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Chemistry Panel</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>HRGOL/AUA Questionnaires</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Research only serum</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Flash frozen prostatectomy specimens</td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Summary of Planned Dose Levels

<table>
<thead>
<tr>
<th>Dose Cohort</th>
<th>Docetaxel dose</th>
<th>Radiation dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0 mg/m²</td>
<td>45 Gy</td>
</tr>
<tr>
<td>2</td>
<td>10 mg/m²</td>
<td>45 Gy</td>
</tr>
<tr>
<td>3</td>
<td>20 mg/m²</td>
<td>45 Gy</td>
</tr>
<tr>
<td>4</td>
<td>30 mg/m²</td>
<td>45 Gy</td>
</tr>
</tbody>
</table>

Trial Significance:

1. This study aims to determine the safety and effectiveness of pre-operative chemoradiation for high risk prostate cancer.
2. This study design may serve as a platform for the screening and identification of novel radio-sensitizers.

Research funding provided by sanofi-aventis (IIT -16179)